

Tihana Bicanic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3677261/publications.pdf>

Version: 2024-02-01

61
papers

6,158
citations

94433

37
h-index

138484

58
g-index

69
all docs

69
docs citations

69
times ranked

4973
citing authors

#	ARTICLE	IF	CITATIONS
1	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. <i>Cell</i> , 2022, 185, 916-938.e58.	28.9	164
2	Tackling the emerging threat of antifungal resistance to human health. <i>Nature Reviews Microbiology</i> , 2022, 20, 557-571.	28.6	311
3	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	5.0	24
4	Presentations and outcomes of central nervous system TB in a UK cohort: The high burden of neurological morbidity. <i>Journal of Infection</i> , 2021, 82, 90-97.	3.3	12
5	AIDS-Related Mycoses. , 2021, , 763-780.		0
6	Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidalty. <i>ACS Infectious Diseases</i> , 2021, 7, 377-389.	3.8	17
7	Fungal Burden and Raised Intracranial Pressure Are Independently Associated With Visual Loss in Human Immunodeficiency Virus-Associated Cryptococcal Meningitis. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab066.	0.9	6
8	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e375-e386.	9.1	80
9	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	4.7	39
10	Cryptococcal meningoencephalitis: time for action. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e259-e271.	9.1	29
11	Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 759408.	3.9	31
12	Invasive candidiasis in critical care: challenges and future directions. <i>Intensive Care Medicine</i> , 2020, 46, 2001-2014.	8.2	73
13	Improving antibiotic stewardship in COVID-19: Bacterial co-infection is less common than with influenza. <i>Journal of Infection</i> , 2020, 81, e55-e57.	3.3	54
14	Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. <i>European Respiratory Journal</i> , 2020, 56, 2002554.	6.7	98
15	Late presentation of amoebic liver abscess. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 259.	9.1	0
16	Genome-Wide Association Study Identifies Novel Colony Stimulating Factor 1 Locus Conferring Susceptibility to Cryptococcosis in Human Immunodeficiency Virus-Infected South Africans. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa489.	0.9	12
17	Case Report: Visceral Leishmaniasis Falsely Diagnosed as Q Fever. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1927-1929.	1.4	2
18	Safety and Efficacy of Intermittent High-Dose Liposomal Amphotericin B Antifungal Prophylaxis in Haemato-Oncology: An Eight-Year Single-Centre Experience and Review of the Literature. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 385.	3.5	7

#	ARTICLE	IF	CITATIONS
19	Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance. <i>MBio</i> , 2019, 10, .	4.1	44
20	Effectiveness of an antifungal stewardship programme at a London teaching hospital 2010â€“16. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 234-241.	3.0	27
21	Leave no one behind: response to new evidence and guidelines for the management of cryptococcal meningitis in low-income and middle-income countries. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e143-e147.	9.1	63
22	Dynamic ploidy changes drive fluconazole resistance in human cryptococcal meningitis. <i>Journal of Clinical Investigation</i> , 2019, 129, 999-1014.	8.2	112
23	Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa. <i>New England Journal of Medicine</i> , 2018, 378, 1004-1017.	27.0	296
24	Transcriptional Profiling of Patient Isolates Identifies a Novel TOR/Starvation Regulatory Pathway in Cryptococcal Virulence. <i>MBio</i> , 2018, 9, .	4.1	5
25	Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. <i>The Cochrane Library</i> , 2018, 2018, CD009012.	2.8	23
26	The <i>Cryptococcus neoformans</i> Titan cell is an inducible and regulated morphotype underlying pathogenesis. <i>PLoS Pathogens</i> , 2018, 14, e1006978.	4.7	137
27	A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection. <i>G3: Genes, Genomes, Genetics</i> , 2017, 7, 1165-1176.	1.8	79
28	AIDS-Related Mycoses: Current Progress in the Field and Future Priorities. <i>Trends in Microbiology</i> , 2017, 25, 428-430.	7.7	16
29	Tracing Genetic Exchange and Biogeography of <i>Cryptococcus neoformans</i> var. <i>grubii</i> at the Global Population Level. <i>Genetics</i> , 2017, 207, 327-346.	2.9	105
30	Genomic epidemiology of <i>Cryptococcus</i> yeasts identifies adaptation to environmental niches underpinning infection across an African HIV/AIDS cohort. <i>Molecular Ecology</i> , 2017, 26, 1991-2005.	3.9	59
31	Cryptococcal meningitis: A neglected NTD?. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005575.	3.0	47
32	Liposomal Amphotericin B (AmBisome®): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. <i>Drugs</i> , 2016, 76, 485-500.	10.9	332
33	<i>Cryptococcus</i> : from environmental saprophyte to global pathogen. <i>Nature Reviews Microbiology</i> , 2016, 14, 106-117.	28.6	387
34	Genotypic Diversity Is Associated with Clinical Outcome and Phenotype in Cryptococcal Meningitis across Southern Africa. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003847.	3.0	94
35	Cerebrospinal Fluid Cytokine Profiles Predict Risk of Early Mortality and Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis. <i>PLoS Pathogens</i> , 2015, 11, e1004754.	4.7	117
36	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7224-7231.	3.2	99

#	ARTICLE	IF	CITATIONS
37	Cryptococcosis diagnosis and treatment: What do we know now. <i>Fungal Genetics and Biology</i> , 2015, 78, 49-54.	2.1	194
38	The <i>Cryptococcus neoformans</i> Transcriptome at the Site of Human Meningitis. <i>MBio</i> , 2014, 5, e01087-13.	4.1	113
39	<i>Cryptococcus neoformans</i> Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> , 2014, 209, 74-82.	4.0	90
40	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. <i>Clinical Infectious Diseases</i> , 2014, 58, 736-745.	5.8	299
41	Very Low Levels of 25-Hydroxyvitamin D Are Not Associated With Immunologic Changes or Clinical Outcome in South African Patients With HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2014, 59, 493-500.	5.8	10
42	Therapy of AIDS-Related Cryptococcal Meningitis. <i>Current Treatment Options in Infectious Diseases</i> , 2014, 6, 294-308.	1.9	2
43	Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2000-2008.	8.2	130
44	Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 629-637.	9.1	151
45	The prevalence of cryptococcal antigenemia in newly diagnosed HIV patients in a Southwest London cohort. <i>Journal of Infection</i> , 2013, 66, 75-79.	3.3	27
46	Adjunctive interferon- γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis. <i>Aids</i> , 2012, 26, 1105-1113.	2.2	238
47	Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis. <i>Clinical Infectious Diseases</i> , 2012, 54, 121-128.	5.8	127
48	Large volume lumbar punctures in cryptococcal meningitis clear cryptococcal antigen as well as lowering pressure. <i>Journal of Infection</i> , 2011, 63, 484-486.	3.3	15
49	Variation in chromosome copy number influences the virulence of <i>Cryptococcus neoformans</i> and occurs in isolates from AIDS patients. <i>BMC Genomics</i> , 2011, 12, 526.	2.8	62
50	Should Antiretroviral Therapy Be Delayed for 10 Weeks for Patients Treated with Fluconazole for Cryptococcal Meningitis?. <i>Clinical Infectious Diseases</i> , 2010, 51, 986-987.	5.8	7
51	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV-Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 702-709.	5.8	201
52	Immune Reconstitution Inflammatory Syndrome in HIV-Associated Cryptococcal Meningitis: A Prospective Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 130-134.	2.1	162
53	High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. <i>Aids</i> , 2009, 23, 1182-1183.	2.2	83
54	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. <i>Aids</i> , 2009, 23, 701-706.	2.2	168

#	ARTICLE	IF	CITATIONS
55	High-Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV-Infected Patients: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2008, 47, 123-130.	5.8	238
56	Reply to Pasqualotto. <i>Clinical Infectious Diseases</i> , 2008, 47, 1110-1111.	5.8	2
57	Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or Fluconazole. <i>Clinical Infectious Diseases</i> , 2007, 45, 76-80.	5.8	261
58	Symptomatic Relapse of HIV-Associated Cryptococcal Meningitis after Initial Fluconazole Monotherapy: The Role of Fluconazole Resistance and Immune Reconstitution. <i>Clinical Infectious Diseases</i> , 2006, 43, 1069-1073.	5.8	210
59	Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: case report and review. <i>Journal of Infection</i> , 2005, 51, e221-e224.	3.3	56
60	Cryptococcal meningitis. <i>British Medical Bulletin</i> , 2004, 72, 99-118.	6.9	286
61	Evaluation of perturbed iron-homeostasis in a prospective cohort of patients with COVID-19. <i>Wellcome Open Research</i> , 0, 7, 173.	1.8	4